Your comment was quite right. A particular medicine, though approved, might not suit every patient.
One of the difficulties we have in New Zealand is that because there is often a sole-supply issue—one medicine in a family of medicines is chosen for funding, and others aren't—clinicians often don't have the choice that we believe would be beneficial to patients.
It's very difficult for somebody if they can't afford a medicine that isn't funded but is a better one for them. Often they have to do the best they can on one that isn't as effective as another one might be. That lack of choice certainly is problematic for our clinicians.